Creating long-lasting treatments for tuberculosis
Official title: Development of sustained release/long acting products for TB
Funded at University of Alabama at Birmingham · NIH-10989407 · Data updated 2026-11-12
This study is looking at new ways to create long-lasting medications for people with latent tuberculosis infection (LTBI), especially those who also have HIV, to make it easier for them to stick to their treatment and help prevent TB from coming back.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $699,668 |
| NIH project number | 7R56AI177262-02 |
| Project ID | NIH-10989407 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with latent TB infection, particularly those who are also HIV positive.
✕Less likely to help
Patients who do not have latent TB infection or are not at risk for TB reactivation may not benefit from this research.
What this research studies
This research focuses on developing sustained release and long-acting formulations for treating latent tuberculosis infection (LTBI), particularly in individuals co-infected with HIV. The approach aims to improve adherence to treatment regimens, which is crucial for preventing the reactivation of TB and the development of drug resistance. By creating formulations that allow for less frequent dosing, the study seeks to enhance the effectiveness of LTBI treatments while minimizing drug interactions with HIV therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective and easier-to-follow treatment options for patients with latent TB, especially those living with HIV.
How similar studies have gone: Other research has shown promise in developing long-acting formulations for various conditions, suggesting potential success for this approach in treating LTBI.
Where this research is happening
-
University of Alabama at Birmingham
Birmingham, United States Active
Researchers
- Principal investigator: Garcia-Martinez, J. Victor — University of Alabama at Birmingham
- Study coordinator: Garcia-Martinez, J. Victor
Related research
Other NIH-funded projects on the same topics.
-
IOP and CSF Pressure in Glaucoma Risk
This grant studies how eye pressure and cerebrospinal fluid pressure together influence glaucoma risk and vision loss.
-
Exploring how Down syndrome affects optic nerve health in kids
A study using a mouse model to understand why optic nerve problems are common in children with Down syndrome and how to prevent them.
-
Global bromocriptine trial for postpartum cardiomyopathy
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with peripartum cardiomyopathy.
-
Global Bromocriptine Add-on for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding the dopamine agonist bromocriptine to standard heart failure care helps postpartum women with a specific heart condition.
-
Global Bromocriptine Trial for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding bromocriptine to standard heart-failure care helps women with postpartum cardiomyopathy.
-
Bromocriptine as add-on therapy for postpartum cardiomyopathy across multiple sites
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with postpartum cardiomyopathy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.